A study conducted in the United States involving 200 children aged 4–6 years found that the seroconversion rates of anti-pertussis antibodies (anti-PT, anti-FHA, and anti-PRN) after one dose of 3-component DTaP were above 90%, with injection site pain, induration, and swelling being the most common AEs38. Here, F2 is linked to pertussis.